Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
“ESSA Pharma (EPIX) is trading for $1.75/share and my estimate of its liquidation value is approximately $2.10/share. 9.5% shareholder BML and 5.1% shareholder Soleus Capital Management have both written public letters to the board pushing for a liquidation. Kevin Tang is also here with a 9.7% stake, but BVF Partners is the largest shareholder at 20%. In the Q1 results (filed after the Soleus & BML letters), EPIX included the line "we have taken productive steps towards a decision and hope to share an update in the near future." That was 53 days ago, hopefully a resolution will take place shortly. BSD Analysis: ESSA Pharma Inc. (EPIX) ESSA is a high-conviction bet on circumventing resistance in the multi-billion-dollar prostate cancer market, challenging the dominance of standard antiandrogen therapies. The company's lead candidate, masofaniten (EPI-7386), is a first-in-class inhibitor that directly targets the N-terminal domain (NTD) of the androgen receptor, a mechanism untouched by existing drugs. Early Phase 2 combination data with enzalutamide showed impressive responses, with high percentages of patients achieving significant Prostate-Specific Antigen (PSA) decline. The edge lies in the potential to delay the emergence of resistance, offering a massive commercial opportunity if these deep, durable responses are confirmed in later-stage trials. EPIX is essentially an aggressive play on owning the next therapeutic line in a vast, underserved oncology market.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
